Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

BACKGROUND: Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not consistently indicative of ICB response. Other markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yinjie, Stein, Michelle M., Kase, Matthew, Cummings, Amy L., Bharanikumar, Ramit, Lau, Denise, Garon, Edward B., Patel, Sandip P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870967/
https://www.ncbi.nlm.nih.gov/pubmed/35881197
http://dx.doi.org/10.1007/s00262-022-03252-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870967/
https://www.ncbi.nlm.nih.gov/pubmed/35881197
http://dx.doi.org/10.1007/s00262-022-03252-y

Ejemplares similares